- history of anaphylactic response to vaccine components. - acute febrile illness. - guillain-barré syndrome, decompensated heart failure (class iii or iv), demyelinating disease. - history of live virus vaccine up to 4 weeks before, virus vaccine inactivated up to 2 weeks before. - history of having received blood products up to 6 months before the study. - individuals who do not accept to participate in the study and/or whose guardians do not agree to participate in the study. - hospitalized patients. - patients with severe conditions requiring hospitalization.

- history of anaphylactic response to vaccine components. - acute febrile illness. - guillain-barré syndrome, decompensated heart failure (class iii or iv), demyelinating disease. - history of live virus vaccine up to 4 weeks before, virus vaccine inactivated up to 2 weeks before. - history of having received blood products up to 6 months before the study. - individuals who do not accept to participate in the study and/or whose guardians do not agree to participate in the study. - hospitalized patients. - patients with severe conditions requiring hospitalization.